Edwards Lifesciences (WBO:EWLS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:EWLS Edwards Lifesciences Corp WBO:EWLS
96 GF Score
Price €80.80
GF Value €82.44
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

WBO:EWLS
96GF Score
Edwards Lifesciences Corp WBO:EWLS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €80.80 is trading 2% below its estimated GF Value™ of €82.44. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for WBO:EWLS:

  • Dividends Received:
  • GF Value™: €82.44 vs. price of €80.80 (2% below fair value)
  • GF Score™: 96/100 with 5 warning signs

No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
96GF Score

Get the complete analysis for WBO:EWLS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€80.80
Price
€82.44
GF Value